Breast最新文献

{"title":"Phyllodes tumors of the breast: Real world data from a multi-institution cohort","authors":"Carl Sars ,&nbsp;Jan Frisell ,&nbsp;Paul W. Dickman ,&nbsp;Felix Haglund de Flon ,&nbsp;Fredrik Karlsson ,&nbsp;Helena Sackey ,&nbsp;Ebba K. Lindqvist","doi":"10.1016/j.breast.2025.104491","DOIUrl":"10.1016/j.breast.2025.104491","url":null,"abstract":"<div><h3>Introduction</h3><div>Phyllodes tumors (PT) are rare breast lesions arising from fibroepithelial stroma and may be hard to clinically distinguish from fibroadenomas. They are defined as benign, borderline or malignant. The purpose of this study was to describe diagnostic workup and surgical management, and to investigate incidence of local recurrence (LR) and overall survival (OS) in relation to tumor subtype, size, age, surgical margins, surgical method, and year of diagnosis.</div></div><div><h3>Methods</h3><div>Retrospective cohort study of all patients surgically treated for a PT in Stockholm, Sweden from 1999 to 2018. Descriptive analyses were performed, and regression models were used to analyze associations between selected covariates and LR and OS.</div></div><div><h3>Results</h3><div>Among 191 patients, 132 were treated for a benign PT, 40 for a borderline PT and 19 for a malignant PT. Preoperatively, results from diagnostic workup were often ambiguous, and only 45.6 % of cases had a preoperative diagnosis of PT. Initial surgery was breast-conserving in 93.2 % of patients. Recurrences occurred in 10.5 % of the total cohort. 5-year and 10-year OS was 96.1 % and 93.5 %, respectively, for the entire cohort. In a multivariable analysis, neither covariate was associated with risk of LR. Distant recurrences were only detected among patients with malignant PT.</div></div><div><h3>Conclusions</h3><div>In the workup of PT, common diagnostic methods such as FNAC, CNB, and mammography may be unreliable, and clinical suspicion plays a critical role in guiding pre-operative decision-making. We found no association between surgical margins and rate of LR or OS. We found no evidence of metastatic potential in benign or borderline PT.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104491"},"PeriodicalIF":5.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma","authors":"Young-Won Lee ,&nbsp;Sae-Byul Lee ,&nbsp;Il Yong Chung ,&nbsp;Jisun Kim ,&nbsp;Hee Jeong Kim ,&nbsp;Beom Seok Ko ,&nbsp;Byung Ho Son ,&nbsp;Jong Won Lee ,&nbsp;Tae-Kyung Robyn Yoo","doi":"10.1016/j.breast.2025.104492","DOIUrl":"10.1016/j.breast.2025.104492","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to compare the efficacy of 5- versus 10-year endocrine therapy in pure mucinous breast carcinoma (PMBC), focusing on late recurrence and related factors for personalized treatment.</div></div><div><h3>Methods</h3><div>Patients with PMBC who underwent surgery from 1996 to 2014 at Asan Medical Center were included. Recurrence was categorized as early (&lt;5 years) or late (≥5 years). The primary endpoint was disease-free survival in the 5- and 10- year endocrine groups. Subgroup analysis was performed focused on clinically high-risk patients (tumor ≥2 cm, nodal metastasis, or high histologic grade).</div></div><div><h3>Results</h3><div>A total of 489 patients with PMBC were identified. During a follow-up time of 126 months, 35 (7.2 %) patients had an early recurrence, 25 (5.1 %) patients had a late recurrence, and 394 (87.7 %) patients had no recurrence. High histologic grade was the only factor significantly correlated to late recurrence (hazard ratio 6.92, 95 % confidence interval 1.53–31.3). Among the 5-year disease-free survivors (N = 416), 340 (81.7 %) and 76 (18.3 %) patients underwent 5-year and 10-year endocrine therapy, respectively. Endocrine therapy duration did not impact the 10-year disease-free survival rate (5-year [95.4 %] vs. 10-year [97.3 %] endocrine therapy, log-rank test p = 0.504). Subgroup analysis with clinically high-risk patients revealed no survival difference based on the endocrine therapy duration, too.</div></div><div><h3>Conclusion</h3><div>Extended endocrine therapy did not significantly reduce late recurrence in PMBC, even in high-risk groups, underscoring the importance of personalized strategies for sustained outcomes.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104492"},"PeriodicalIF":5.7,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143929159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the global, national, and regional burden of breast cancer among adolescents and young adults from 1990 to 2021: Analyses of the 2021 global burden of disease study","authors":"Da Qian ,&nbsp;Weimin Hong ,&nbsp;Shujin Li ,&nbsp;Haotian Liu ,&nbsp;Chaoqi He ,&nbsp;Xiaozhen Liu ,&nbsp;Guoxin Huang ,&nbsp;Xuli Meng ,&nbsp;Yiwen Zheng","doi":"10.1016/j.breast.2025.104486","DOIUrl":"10.1016/j.breast.2025.104486","url":null,"abstract":"<div><h3>Background</h3><div>This study was devised to evaluate the burden of breast cancer (BC) among adolescents and young adults (AYAs) between 1990 and 2021.</div></div><div><h3>Methods</h3><div>BC burden among AYAs (15–39 years of age) was analyzed by examining the associated age-standardized incidence rate, age-standardized prevalence rate, age-standardized death rate, and age-standardized disability-adjusted life year (DALY) rates between 1990 and 2021 at the global, national, and regional levels, together with corresponding analyses of health inequality and decomposition analyses.</div></div><div><h3>Results</h3><div>In 2021, the respective global age-standardized incidence rate, age-standardized prevalence rate, age-standardized death rate, and age-standardized DALYs for BC were 5.87 (5.39,6.41), 49.35 (45.46,53.86), 1.37 (1.24,1.51), and 80.8 (72.84,89.23), which respectively showed increases of 33.4 %, 35.2 %, 1.5 %, and 3.3 % compared to the rate of 1990. While women comprise the vast majority of all BC cases, a higher average annual percent change was observed for males relative to females at the global level. The average annual percent change for BC incidence, prevalence, death, and DALYs among men AYAs (2.59, 2.49, 1.06, 1.10) were all higher than the corresponding values among women (0.91, 0.96, 0.02, 0.09). Regional and national differences in disease burden were observed. BC disease burden was significantly positively correlated with socio-demographic index (SDI). Similar trends were observed in terms of female disease burden, whereas disease burden of male patients was negatively related to SDI. In decomposition analyses, the primary factors associated with changes in age-standardized DALY rates were identified as aging and population growth. Health inequality analyses revealed that the burden of BC among AYAs was particularly concentrated in lower-income countries.</div></div><div><h3>Conclusions</h3><div>These results highlight that the burden of BC among AYAs has grown in recent decades, while also emphasizing the need to be attentive to the rising occurrence of male BC. Lower-income regions also faced a heavier BC-related burden as compared to more affluent nations. Efforts to reduce the disease burden associated with BC may thus hinge on government-based initiatives focused on improving overall national economic strength and medical system quality.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104486"},"PeriodicalIF":5.7,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists","authors":"Hope S. Rugo ,&nbsp;Aditya Bardia ,&nbsp;William J. Gradishar ,&nbsp;Erika P. Hamilton ,&nbsp;Sara A. Hurvitz ,&nbsp;Komal Jhaveri ,&nbsp;Reshma Mahtani ,&nbsp;Sara M. Tolaney","doi":"10.1016/j.breast.2025.104485","DOIUrl":"10.1016/j.breast.2025.104485","url":null,"abstract":"<div><div>Hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2-mBC) is incurable, but recent progress has been made in developing new treatment options and the treatment landscape is rapidly shifting. There are published recommendations for treatment choices and sequencing to help guide oncologists in treating HR+/HER2-mBC, but little evidence has been published regarding real-world practice patterns. The REal-world TReatment patterns And Considerations of Toxicity in HR+/HER2-mBC (RETRACT) survey was designed to evaluate real-world practice patterns in the testing and management of this disease by US oncologists. The survey questions were answered via an online platform and the data were anonymized before analysis. A total of 150 oncologists practicing at academic and community centers completed the survey. The results showed this sample of oncologists largely followed recommended best practices for testing biomarkers, selecting treatments, and managing adverse events. However, several items did show substantial minorities of oncologists not in alignment with recommendations in areas including the definition and treatment of visceral crisis, ideal treatment for patients with endocrine resistance, the routine use of next-generation sequencing for biomarker testing, and the use of prophylactic measures for treatment-related adverse events in patients receiving alpelisib.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104485"},"PeriodicalIF":5.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143916784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of Breast Cancer in European female adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results","authors":"Alice Bernasconi ,&nbsp;Angela Toss ,&nbsp;Emma Zattarin ,&nbsp;Seyed Mohsen Mousavi ,&nbsp;Marcel Blum ,&nbsp;Claudia E. Kuehni ,&nbsp;Alexander Katalinic ,&nbsp;Jan Trallero ,&nbsp;Elisabetta Rapiti ,&nbsp;Luigino Dal Maso ,&nbsp;Laura Botta ,&nbsp;Silvia Rossi ,&nbsp;Fedro Peccatori ,&nbsp;Annalisa Trama ,&nbsp;the EUROCARE-6 Working Group","doi":"10.1016/j.breast.2025.104472","DOIUrl":"10.1016/j.breast.2025.104472","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer (BC) is the most common malignancy in AYA (15–39 years) females and is more aggressive than in adult women (40–69 years). However, an updated overview on BC in AYAs and how it differs from BC in adult women is lacking.</div></div><div><h3>Methods</h3><div>We used data from the EUROCARE-6 study to calculate incidence rates (IRs) of BC in AYA and adult women over the period 2001–2013 in Europe. We estimated 5-year and 10-year relative survival (RS) using period analysis. Stage at diagnosis distribution and conditional RS (CS) were used to investigate survival differences. We also reported cumulative incidence of multiple primary neoplasms (MPNs) in AYAs.</div></div><div><h3>Results</h3><div>The IR of BC in Europe was ∼18 per 100,000 in AYA females and more than ten-fold higher in adult women. Most BC cases were diagnosed at Stages I-II (74 % in AYAs vs 77 % in adults). Overall, AYAs had lower 5-year RS than adult women (85.0 % vs 89.5 %, respectively); the survival gap slightly decreased in CS. AYAs had worse survival than adult women for early stage and Stage III but better RS for Stage IV (5-year RS 31.5 % vs. 26.3 %). Cumulative incidence of all MPNs in AYAs was ∼6 % at 14 years from BC diagnosis.</div></div><div><h3>Conclusions</h3><div>Our findings support the more aggressive behavior of BC in AYAs. The high proportion of early stage at diagnosis is reassuring considering that organized BC screening is not available for AYAs in Europe. Conversely, the incidence of MPNs in AYAs is relevant and might deserve a revision of follow-up strategies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104472"},"PeriodicalIF":5.7,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A population-based estimation of breast cancer recurrence in northeast Italy with administrative healthcare databases","authors":"Fabiola Giudici ,&nbsp;Federica Toffolutti ,&nbsp;Stefano Guzzinati ,&nbsp;Francesco Schettini ,&nbsp;Marina Bortul ,&nbsp;Silvia Francisci ,&nbsp;Manuel Zorzi ,&nbsp;Sara De Vidi ,&nbsp;Daniela Pierannunzio ,&nbsp;Luigino Dal Maso","doi":"10.1016/j.breast.2025.104487","DOIUrl":"10.1016/j.breast.2025.104487","url":null,"abstract":"<div><h3>Background/Aim</h3><div>Information on the long-term frequency of recurrence is of paramount importance for the increasing number of women living several years after breast cancer (BC) diagnosis and for their caregivers.</div><div>The study aims to estimate the cumulative incidence of recurrence until 10 years after diagnosis in Italian women diagnosed with BC using population-based cancer registries.</div></div><div><h3>Methods</h3><div>Women diagnosed with stage I to III BC during 2004–2010 from Friuli Venezia Giulia and Veneto (Italy) cancer registries were included (n = 5825). Recurrence status after a disease-free period was ascertained through individual-level linked databases using treatment or procedure codes from claims. Cumulative incidence of recurrence was calculated in the presence of competing risks (second cancer or death).</div></div><div><h3>Results</h3><div>During a median follow-up of 13.5 years, 1522 out of 5825 women experienced a recurrence with an estimated 10-years cumulative incidence of 20.8 % (95 %CI:19.7–21.8 %), decreasing from 23.7 % in 2004–2006 to 18.5 % in 2007–2010. Women younger than 40 years (40.5 %), with stage III (41.8 %) and triple-negative BC (32.5 %) showed a higher 10-year incidence of recurrence.</div><div>At 10 years after a BC diagnosis, 83.9 % of women were alive: 67.5 % without any cancer-related events, 12.4 % after recurrence and 4.0 % after second primary cancer. 10-years survival was higher than 90 % for women with stage I BC and 58.1 % for those with stage III (3.2 % and 27.3 % deaths after recurrence, respectively).</div></div><div><h3>Discussion</h3><div>This Italian study provide detailed population-based information on the incidence of recurrence and other outcomes after BC and may be replicated in other Italian and European areas.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104487"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143911729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Beta blocker use and breast cancer survival by subtypes: A population-based cohort study” [The Breast 81 (2025) 104474]","authors":"Oliver William Scott ,&nbsp;Sandar Tin Tin ,&nbsp;Edoardo Botteri","doi":"10.1016/j.breast.2025.104478","DOIUrl":"10.1016/j.breast.2025.104478","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104478"},"PeriodicalIF":5.7,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a 10-gene signature for predicting recurrence risk in HR+/HER2- early breast cancer undergoing chemo-endocrine therapy","authors":"Xiaoyan Wu ,&nbsp;Xunxi Lu ,&nbsp;Wenchuan Zhang ,&nbsp;Xiaorong Zhong ,&nbsp;Hong Bu ,&nbsp;Zhang Zhang","doi":"10.1016/j.breast.2025.104484","DOIUrl":"10.1016/j.breast.2025.104484","url":null,"abstract":"<div><h3>Background</h3><div>While existing multi-gene assays aid adjuvant treatment decisions, no gene signature has identified HR+/HER2- early breast cancer (EBC) patients at high recurrence risk post-chemo-endocrine therapy (C-ET).</div></div><div><h3>Methods</h3><div>Clinical data and RNA sequencing information from 1457 HR+/HER2- breast cancer patients were collected from West China Hospital, the GEO database, and the TCGA database. Using univariate Cox regression, gene set enrichment analysis, and LASSO regression, ten key genes associated with recurrence were identified. A comprehensive prognostic model was developed by combining the 10-gene risk score with clinicopathological features, and a nomogram was created to predict 3-, 5-, and 7-year recurrence-free survival (RFS). The model's performance was evaluated using AUC and decision curve analysis (DCA).</div></div><div><h3>Results</h3><div>The 10-gene risk score was significantly associated with recurrence risk of HR+/HER2- EBC after C-ET and effectively distinguished between high-risk and low-risk patients (training: HR: 6.37, <em>P</em> &lt; 0.001; validation: HR: 4.51, <em>P</em> &lt; 0.001). It maintained consistent stratification efficacy across different treatment regimens, clinical stages, and grades. Compared to existing multi-gene signatures (21-gene, 70-gene, EndoPredict, PAM50, GGI), HR+/HER2- EBC patients identified as high-risk by the 10-gene risk score exhibited a higher 10-year cumulative recurrence rate following C-ET. In multivariate Cox regression analysis, the 10-gene risk score remained an independent prognostic factor in both the training and validation sets. The comprehensive model, integrating the 10-gene score and clinicopathological features, showed high predictive accuracy (AUC: 0.734, 0.778, 0.792 for 3, 5, 7 years in training; 0.691, 0.715, 0.709 in validation).</div></div><div><h3>Conclusion</h3><div>The 10-gene risk score can serve as a tool to predict recurrence risk in HR+/HER2- EBC patients following C-ET, assisting clinicians in developing personalized treatment plans for high-risk patients and ultimately improving patient prognosis.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104484"},"PeriodicalIF":5.7,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physicians’ knowledge, practice, and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: results of the ABC6 and ABC7 survey","authors":"Simone Nardin ,&nbsp;Luca Arecco ,&nbsp;Virginia Delucchi ,&nbsp;Eva Blondeaux ,&nbsp;Mihaela Stana ,&nbsp;Luciana de Moura Leite ,&nbsp;Luiza Nardin Weis ,&nbsp;Giang Pham Hoang ,&nbsp;Arianna Daneri ,&nbsp;Francesca Bruzzone ,&nbsp;Arianna Meacci ,&nbsp;Chiara Molinelli ,&nbsp;Maria Grazia Razeti ,&nbsp;Martina Perrone ,&nbsp;Shani Paluch-Shimon ,&nbsp;Ann H. Partridge ,&nbsp;Fatima Cardoso ,&nbsp;Tanja Spanic ,&nbsp;Joanna Kufel-Grabowska ,&nbsp;Matteo Lambertini","doi":"10.1016/j.breast.2025.104479","DOIUrl":"10.1016/j.breast.2025.104479","url":null,"abstract":"<div><h3>Background</h3><div>Fertility and pregnancy-related issues are critical for young patients with breast cancer. No proper evidence exists on physicians' knowledge, practice, and attitudes on dealing with these concerns in the specific group of patients with advanced disease.</div></div><div><h3>Methods</h3><div>A 26-item questionnaire was administered via e-mail in December 2023 to physicians who attended the ABC6 consensus conference (virtually, November 2021) and those who were registered for the ABC7 consensus conference (Lisbon, November 2023). The questionnaire was divided into 3 main sections: 1) demographic, medical training, and background information; 2) knowledge, practice, and attitudes of physicians towards fertility preservation and pregnancy-related issues in patients with advanced breast cancer; 3) approach to hypothetical clinical cases.</div></div><div><h3>Results</h3><div>A total of 133 physicians completed the survey. Most reported discussing always (40.6 %) or usually (36.1 %) the possible treatment-related loss of ovarian function in patients with advanced breast cancer. Regarding fertility preservation and pregnancy-related issues, 23.3 % would always feel comfortable discussing these topics with patients, and 45.9 % would feel comfortable depending on the clinical situation. 20.3 % reported not prescribing any type of contraception, and 10–20 % would prescribe treatments that are contraindicated during pregnancy.</div></div><div><h3>Conclusions</h3><div>Our survey showed that many concerns exist when discussing and dealing with fertility and pregnancy-related issues in patients with advanced breast cancer. It is essential to increase physicians' awareness on how to address fertility and pregnancy-related issues in patients with advanced breast cancer, especially as oncological treatments continue to improve, resulting in longer survival and, in some cases, potential cure.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104479"},"PeriodicalIF":5.7,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143911728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of AI-based pre-hospital health education via QR code on APAIS scores in patients with breast nodules: A retrospective study","authors":"Guozhen Ma ,&nbsp;Chuyuan Miao ,&nbsp;Pengjun Jiang ,&nbsp;Guiqing He ,&nbsp;Huiping Li ,&nbsp;Yanhui Huang ,&nbsp;Huiwen Yu ,&nbsp;Tianwen Chen","doi":"10.1016/j.breast.2025.104481","DOIUrl":"10.1016/j.breast.2025.104481","url":null,"abstract":"<div><h3>Purpose</h3><div>To explore the effect of AI-based pre-hospital health education via QR code on preoperative anxiety and information needs in patients with breast nodules and provide a decision-making reference for ongoing optimizing clinical workflows.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed the clinical data of 718 breast nodule patients from January to December 2024. Patients were sequentially divided into a non-viewed group (receiving routine health education) and a viewed group (receiving AI-based pre-hospital health education) to compare Amsterdam Preoperative Anxiety and Information Scale (APAIS) scores between the two groups. Univariate analysis and multivariate regression were used to examine factors influencing preoperative anxiety and information needs in patients with breast nodules.</div></div><div><h3>Results</h3><div>718 patients were included, with 367 in the non-viewed group and 351 in the viewed group. Patients in the viewed group reported higher satisfaction scores and had shorter hospital stay compared to those in the non-viewed group. The multiple linear regression analysis revealed a significant negative correlation between the viewed group and preoperative anxiety (<em>β</em> = −5.31, 95 % CI: −6.03, −4.59; <em>P</em> = 0.001) and information needs (<em>β</em> = −1.40, 95 % CI: −1.63, −1.18; <em>P</em> = 0.001). Additionally, patient satisfaction also influences their preoperative anxiety and information needs (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>AI-based pre-hospital health education can help reduce patients with breast nodules' preoperative anxiety and information needs, as well as increase their satisfaction and shorten hospital stay. AI-based pre-hospital health education via QR code can be applied in clinical practice.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"82 ","pages":"Article 104481"},"PeriodicalIF":5.7,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143934850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}